Farglitazar

Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.

PPAR

Reference compound

Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor

Metabolism-protein/nucleotide metabolism

Metabolic Disease

https://www.medchemexpress.com/farglitazar.html

99.50

DMSO : 100 mg/mL (ultrasonic)

O=C(C1=CC=CC=C1)C2=C(C=CC=C2)N[C@H](C(O)=O)CC3=CC=C(C=C3)OCCC4=C(C)OC(C5=CC=CC=C5)=N4

546.61

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

http://file.medchemexpress.com/batch_PDF/HY-105074/Farglitazar-DataSheet-MedChemExpress.pdf

http://file.medchemexpress.com/batch_PDF/HY-105074/Farglitazar-SDS-MedChemExpress.pdf

Phase 3

196808-45-4